Several studies have shown an increased risk of colorectal and extracolonic cancers for carriers of germline MUTYH mutations inherited from both parents (biallelic mutations). Extracolonic cancer risks for carriers of a MUTYH mutation inherited from only one parent (monoallelic mutation) have not previously been estimated.
Materials and methods
We identified 144 families of MUTYH mutation carriers from three countries that we ascertained through population-based sources of the multi-site, international Colon Cancer Family Registry. Mutation status, sex, age, and histories of cancer, polypectomy, and hysterectomy were sought from 2,179 of their relatives. Using Cox regression weighted to adjust for the method of ascertainment, we estimated the country-, age-and sex-specific standardized incidence ratios (SIRs) of colorectal and extracolonic cancers for monoallelic mutation carriers, compared with the general population, and corresponding age-specific cumulative risks.
Results
Monoallelic mutation carriers with a family history of CRC had a significantly increased incidence of CRC (SIR = 2.04; 95% confidence interval, CI = 1.56 -2.70; P <0.001), gastric cancer (SIR = 3.24; 95% CI = 2.18 -4.98; P <0.001), and endometrial cancer (SIR = 2.23; 95% CI = 1.13 -4.86; P = 0.03) and a marginal increased incidence of liver cancer (SIR = 3.09; 95% CI = 1.07 -12.25; P = 0.07) compared to the general population. The estimated cumulative risks to age 70 years based on the population cancer incidence of the United States were as follows: for CRC, 6% (95% CI = 5 -%) for men and 4% (95% CI = 3 -6%) for women; for gastric cancer, 2% (95% CI = 1 -3%) for men and 0.7% (95% CI = 0.5 -1%) for women; for liver cancer, 1% (95% CI = 0.3 -3%) for men and 0.3% (95% CI = 0.1 -1%) for women; and for endometrial cancer, 4% (95% CI = 2 -8%). There was no evidence of increased risks for cancer of the brain, pancreas, kidney, lung, breast or prostate.
Conclusion
Monoallelic MUTYH mutation carriers with a family history of CRC are at increased risk of colorectal, gastric, liver and endometrial cancers.
